7 for semaglutide) were reported during the study period
Current Obesity Reports, 12 (2), 99107
Our team of NPs and Doctors at the Memorial office provides a full medical assessment and Blood Panel to ensure your protocol is safe and effective for your specific goals
In the run-in period, all patients, regardless of whether we are randomized to receive lira or placebo later, were subject to a hypocaloric diet and exercise regime, without GLP-1 receptor agonist, with the duration of the period for each patient being the time required to lose 5% of their baseline body weight In the STEP trials (Table 1), designed to evaluate the efficacy and safety of semaglutide 2.4mg (subcutaneous, weekly) in patients with obesity, or excess weight (BMI 27kg/m2) with complications, weight loss of between 15% and 17% was achieved 68 weeks after starting treatment.7678 In one of the trials, weight loss of 10% was reported after 20 weeks of therapy
[DOI] [PMC free article] [PubMed] [Google Scholar] 102
